Gly-Leu

CAS: 869-19-2

Ref. 3D-OGL-3022

Información del producto

• Nombre: Gly-Leu
• Sinónimos: Glycyl-L-Leucine, (2S)-2-(2-Aminoacetamido)-4-methylpentanoic acid, (2S)-2-[(2-Aminoacetyl)amino]-4-methylpentanoic acid, 117: PN: US20130123467 SEQID: 141 claimed protein, 17: PN: KR20140043582 SEQID: 20 claimed protein, 4: PN: WO2014170713 SEQID: 104 claimed protein, 98: PN: EP2161028 PAGE: 10 claimed protein, <span class="text-smallcaps">L</span>-Leucine, N-glycyl-, <span class="text-smallcaps">L</span>-Leucine, glycyl-, Glycyl-<span class="text-smallcaps">L</span>-leucine, Glycylleucine, L-Leucine, N-glycyl-, Leucine, N-glycyl-, <span class="text-smallcaps">L</span>-, Leucine, N-glycyl-, L-, N-Glycyl-<span class="text-smallcaps">L</span>-leucine, Nsc 83257

Descripción

Gly-Leu is a cyclic peptide that was originally isolated from human serum. It has been shown to have antibiotic activity against bacteria such as Escherichia coli and Staphylococcus aureus. This drug also inhibits the enzyme activities of trifluoroacetic acid, sodium citrate, and calcium binding. Gly-Leu has been shown to have anti-tumour properties in vivo by inhibiting the growth of carcinoma cell lines and inducing apoptosis in these cells. It also has immunomodulatory effects on autoimmune diseases such as multiple sclerosis.

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 188.22 g/mol
• Fórmula: C₈H₁₆N₂O₃
• Pureza: Min. 95%